ArticleHuman vaccines & immunotherapeutics2026
Absence of autoantibodies linked to cancer and autoimmune disorders 26 weeks after BNT162b2 boosting in CoronaVac- primed individuals.
Article in Human vaccines & immunotherapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- COVID-19 mRNA Vaccines as Antigen-Agnostic Immunomodulators: A Repurposing Perspective.Medical sciences (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Concerns regarding vaccine-associated autoimmunity and activation of cancer-related pathways persist, yet longitudinal proteome-wide evaluations of heterologous COVID-19 vaccination regimens remain limited. Here, we assessed the stability of the human 'autoantibodyome' in 30 healthy adults receiving a heterologous CoronaVac-BNT162b2 vaccination regimen (inactivated-virus priming followed by an mRNA booster). Paired serum samples collected pre-vaccination and 26 weeks post-booster were analyzed using the i-Ome™ Discovery protein microarray, which measures IgG reactivity against 1,610 native human antigens associated with autoimmune and oncogenic pathways. After quality-control filtering, 534 high-confidence autoantigens were retained for downstream analysis. Across this panel, autoantibody profiles remained highly stable over time. Linear modeling with false discovery rate correction (FDR > 0.05) and receiver operating characteristic analysis (AUC 0.59-0.67) identified no statistically significant changes in autoantibody reactivity. Principal component analysis demonstrated substantial overlap between pre-vaccination and 26-week post-booster samples, indicating that no combinatorial autoantibody signature distinguished the two timepoints. In stratified analyses, mild breakthrough SARS-CoV-2 infection did not promote aberrant autoantibody production. Within the scope of this high-resolution 1,610-antigen platform, these findings provide proteome-wide evidence that heterologous BNT162b2 boosting after CoronaVac priming is not associated with sustained induction of IgG autoantibodies linked to autoimmune or cancer-related pathways. These findings provide proteome-wide safety evidence supporting the immunological stability of the circulating autoantibody repertoire following mixed-platform COVID-19 vaccination in healthy adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.